Targeting Metabolic Reprogramming in Polycystic Kidney Disease
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Raez L, Papadopoulos K, Ricart A, Chiorean E, DiPaola R, Stein M
. A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2012; 71(2):523-30.
DOI: 10.1007/s00280-012-2045-1.
View
2.
DeBerardinis R, Lum J, Hatzivassiliou G, Thompson C
. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008; 7(1):11-20.
DOI: 10.1016/j.cmet.2007.10.002.
View
3.
Chiaravalli M, Rowe I, Mannella V, Quilici G, Canu T, Bianchi V
. 2-Deoxy-d-Glucose Ameliorates PKD Progression. J Am Soc Nephrol. 2015; 27(7):1958-69.
PMC: 4926967.
DOI: 10.1681/ASN.2015030231.
View
4.
Podrini C, Rowe I, Pagliarini R, Costa A, Chiaravalli M, Di Meo I
. Dissection of metabolic reprogramming in polycystic kidney disease reveals coordinated rewiring of bioenergetic pathways. Commun Biol. 2018; 1:194.
PMC: 6240072.
DOI: 10.1038/s42003-018-0200-x.
View
5.
Rowe I, Chiaravalli M, Mannella V, Ulisse V, Quilici G, Pema M
. Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nat Med. 2013; 19(4):488-93.
PMC: 4944011.
DOI: 10.1038/nm.3092.
View